{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:50:23Z","timestamp":1794441023417,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Special Financial Grant Project of Fujian University of Traditional Chinese Medicine","award":["NO. X2021003"],"award-info":[{"award-number":["NO. X2021003"]}]},{"name":"the Special Financial Grant Project of Fujian University of Traditional Chinese Medicine","award":["NO. X2021003"],"award-info":[{"award-number":["NO. X2021003"]}]},{"name":"the Special Financial Grant Project of Fujian University of Traditional Chinese Medicine","award":["NO. X2021003"],"award-info":[{"award-number":["NO. X2021003"]}]},{"name":"the Special Financial Grant Project of Fujian University of Traditional Chinese Medicine","award":["NO. X2021003"],"award-info":[{"award-number":["NO. X2021003"]}]},{"name":"the Special Financial Grant Project of Fujian University of Traditional Chinese Medicine","award":["NO. X2021003"],"award-info":[{"award-number":["NO. X2021003"]}]},{"name":"the Special Financial Grant Project of Fujian University of Traditional Chinese Medicine","award":["NO. X2021003"],"award-info":[{"award-number":["NO. X2021003"]}]},{"name":"the Special Financial Grant Project of Fujian University of Traditional Chinese Medicine","award":["NO. X2021003"],"award-info":[{"award-number":["NO. X2021003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17182-z","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:20:25Z","timestamp":1756711225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A comprehensive study on drug-related Raynaud\u2019s phenomenon based on the FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Pingping","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzhuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"17182_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101474","volume":"34","author":"AL Herrick","year":"2020","unstructured":"Herrick, A. L. & Wigley, F. M. Raynaud\u2019s phenomenon. Best Pract. Res. Clin. Rheumatol. 34, 101474 (2020).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"17182_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","volume":"20","author":"A Haque","year":"2020","unstructured":"Haque, A. & Hughes, M. Raynaud\u2019s phenomenon. Clin. Med. 20, 580\u2013587 (2020).","journal-title":"Clin. Med."},{"key":"17182_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","volume":"48\u201349","author":"E Maverakis","year":"2014","unstructured":"Maverakis, E. et al. International consensus criteria for the diagnosis of Raynaud\u2019s phenomenon. J. Autoimmun. 48\u201349, 60\u201365 (2014).","journal-title":"J. Autoimmun."},{"key":"17182_CR4","volume":"12","author":"F Rirash","year":"2017","unstructured":"Rirash, F. et al. Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon. Cochrane Database Syst. Rev. 12, CD000467 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"17182_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1358863X20983455","volume":"26","author":"E Choi","year":"2021","unstructured":"Choi, E. & Henkin, S. Raynaud\u2019s phenomenon and related vasospastic disorders. Vasc. Med. 26, 56\u201370 (2021).","journal-title":"Vasc. Med."},{"key":"17182_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006389","volume":"5","author":"R Garner","year":"2015","unstructured":"Garner, R., Kumari, R., Lanyon, P., Doherty, M. & Zhang, W. Prevalence, risk factors and associations of primary Raynaud\u2019s phenomenon: Systematic review and meta-analysis of observational studies. BMJ Open 5, e006389 (2015).","journal-title":"BMJ Open"},{"key":"17182_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/annrheumdis-2024-eular.3318","volume":"83","author":"F Dernie","year":"2024","unstructured":"Dernie, F., Prats-Uribe, A., Man, W. Y., Delmestri, A. & Prieto-Alhambra, D. POS1412 incidence, prevalence, and baseline characteristics of primary and secondary Raynaud\u2019s phenomenon in the United Kingdom, 2000\u20132022: A population-based cohort study. Ann. Rheum. Dis. 83, 674\u2013675 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"17182_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1526-2","volume-title":"Raynaud\u2019s Phenomenon: A Guide to Pathogenesis and Treatment","author":"F Wigley","year":"2015","unstructured":"Wigley, F., Herrick, A. & Flavahan, N. Raynaud\u2019s Phenomenon: A Guide to Pathogenesis and Treatment (Springer, 2015)."},{"key":"17182_CR9","volume":"15","author":"AC Falls","year":"2023","unstructured":"Falls, A. C., Wrigley, C. & Khanna, S. A. Progressive systemic sclerosis with negative antinuclear antibodies and absence of Raynaud\u2019s phenomenon: A case report and literature review. Cureus J. Med. Sci. 15, e35663 (2023).","journal-title":"Cureus J. Med. Sci."},{"key":"17182_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bcp.12912","volume":"82","author":"C Khouri","year":"2016","unstructured":"Khouri, C. et al. Drug-induced Raynaud\u2019s phenomenon: Beyond \u03b2-adrenoceptor blockers. Br. J. Clin. Pharmacol. 82, 6\u201316 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"17182_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M., Raschi, E., Poluzzi, E. & Hauben, M. The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin. Drug Saf. 23, 981\u2013994 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"17182_CR12","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1038\/s41598-025-87421-w","volume":"15","author":"N Lee","year":"2025","unstructured":"Lee, N., Ok, J. H., Rhee, S. & Kim, Y. Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system. Sci. Rep. UK 15, 5675 (2025).","journal-title":"Sci. Rep. UK"},{"key":"17182_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","volume":"23","author":"AO G\u00e9rard","year":"2022","unstructured":"G\u00e9rard, A. O. et al. Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: A real-world potential safety signal from the WHO pharmacovigilance database. J. Headache Pain 23, 53 (2022).","journal-title":"J. Headache Pain"},{"key":"17182_CR14","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1111\/bcp.14322","volume":"86","author":"P Zaza","year":"2020","unstructured":"Zaza, P., Matthieu, R., Jean-Luc, C. & Charles, K. Drug repurposing in Raynaud\u2019s phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. Br. J. Clin. Pharmacol. 86, 2217\u20132222 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"17182_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaad.2022.06.1199","volume":"90","author":"P Curtiss","year":"2024","unstructured":"Curtiss, P., Svigos, K., Schwager, Z., Lo Sicco, K. & Franks, A. G. J. Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud\u2019s phenomenon. J Am. Acad. Dermatol. 90, 223\u2013234 (2024).","journal-title":"J Am. Acad. Dermatol."},{"key":"17182_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105841","volume":"164","author":"V Parlatini","year":"2024","unstructured":"Parlatini, V., Bellato, A., Murphy, D. & Cortese, S. From neurons to brain networks, pharmacodynamics of stimulant medication for ADHD. Neurosci. Biobehav. Rev. 164, 105841 (2024).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"17182_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","volume":"375","author":"FM Wigley","year":"2016","unstructured":"Wigley, F. M. & Flavahan, N. A. Raynaud\u2019s phenomenon. N. Engl. J. Med. 375, 556\u2013565 (2016).","journal-title":"N. Engl. J. Med."},{"key":"17182_CR18","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2023","unstructured":"Sun, W. et al. Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: A real-world study based on the FDA adverse event reporting system. Front. Pharmacol. 14, 1257282 (2023).","journal-title":"Front. Pharmacol."},{"key":"17182_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40263-024-01154-4","volume":"39","author":"FMC Besag","year":"2025","unstructured":"Besag, F. M. C., Vasey, M. J., Roy, S. & Cortese, S. Raynaud syndrome associated with medication for attention-deficit\/hyperactivity disorder: A systematic review. CNS Drugs 39, 213\u2013241 (2025).","journal-title":"CNS Drugs"},{"key":"17182_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00431-023-05370-w","volume":"183","author":"L Van Vyve","year":"2024","unstructured":"Van Vyve, L. et al. Pharmacotherapy for ADHD in children and adolescents: A summary and overview of different European guidelines. Eur. J. Pediatr. 183, 1047\u20131056 (2024).","journal-title":"Eur. J. Pediatr."},{"key":"17182_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1024\/0301-1526\/a000661","volume":"46","author":"J Belch","year":"2017","unstructured":"Belch, J. et al. ESVM guidelines\u2014The diagnosis and management of Raynaud\u2019s phenomenon. VASA 46, 413\u2013423 (2017).","journal-title":"VASA"},{"key":"17182_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1526-4610.2012.02300.x","volume":"53","author":"MJ Stillman","year":"2013","unstructured":"Stillman, M. J., Tepper, S., Tepper, D. E. & Cho, L. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: Review of serotonergic cardiac adverse events with a triptan case. Headache 53, 208\u2013216 (2013).","journal-title":"Headache"},{"key":"17182_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1113\/eph8802574","volume":"88","author":"Y Takemoto","year":"2003","unstructured":"Takemoto, Y. Hindquarters vasoconstriction through central GABA(B) receptors in conscious rats. Exp. Physiol. 88, 491\u2013496 (2003).","journal-title":"Exp. Physiol."},{"key":"17182_CR24","doi-asserted-by":"publisher","first-page":"zsad161","DOI":"10.1093\/sleep\/zsad161","volume":"46","author":"RH Ben-Joseph","year":"2023","unstructured":"Ben-Joseph, R. H. et al. Cardiovascular burden of narcolepsy disease (CV-BOND): A real-world evidence study. Sleep 46, zsad161 (2023).","journal-title":"Sleep"},{"key":"17182_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/17460441.2022.1999226","volume":"17","author":"G Junnarkar","year":"2022","unstructured":"Junnarkar, G. et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin. Drug Dis. 17, 109\u2013119 (2022).","journal-title":"Expert Opin. Drug Dis."},{"key":"17182_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/sarh.2002.34606","volume":"32","author":"D Schapira","year":"2002","unstructured":"Schapira, D., Nahir, A. M. & Hadad, N. Interferon-induced Raynaud\u2019s syndrome. Semin. Arthritis Rheum. 32, 157\u2013162 (2002).","journal-title":"Semin. Arthritis Rheum."},{"key":"17182_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S2213-2600(24)00267-4","volume":"13","author":"S Sehgal","year":"2025","unstructured":"Sehgal, S. et al. Idiopathic inflammatory myopathies related lung disease in adults. Lancet Respir. Med. 13, 272\u2013288 (2025).","journal-title":"Lancet Respir. Med."},{"key":"17182_CR28","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1093\/rheumatology\/keaf128","volume":"64","author":"A Gomez","year":"2025","unstructured":"Gomez, A. et al. Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting. Rheumatology 64, 3797\u20133805 (2025).","journal-title":"Rheumatology"},{"key":"17182_CR29","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon, J. K. et al. Belimumab for the treatment of early diffuse systemic sclerosis: Results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol. 70, 308\u2013316 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"17182_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40264-024-01404-w","volume":"47","author":"Y Noguchi","year":"2024","unstructured":"Noguchi, Y. & Yoshimura, T. Detection algorithms for simple two-group comparisons using spontaneous reporting systems. Drug Saf. 47, 535\u2013543 (2024).","journal-title":"Drug Saf."},{"key":"17182_CR31","doi-asserted-by":"publisher","first-page":"18645","DOI":"10.1038\/s41598-025-02723-3","volume":"15","author":"L Zhang","year":"2025","unstructured":"Zhang, L., Yang, M., Zhang, Y., Lan, J. & Chen, Q. Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: Insights from FAERS and scRNA-seq data. Sci. Rep. UK 15, 18645 (2025).","journal-title":"Sci. Rep. UK"},{"key":"17182_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): Development and statement. Drug Saf. 47, 585\u2013599 (2024).","journal-title":"Drug Saf."},{"key":"17182_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2023.116385","volume":"339","author":"KMN Lee","year":"2023","unstructured":"Lee, K. M. N. et al. A gender hypothesis of sex disparities in adverse drug events. Soc. Sci. Med. 339, 116385 (2023).","journal-title":"Soc. Sci. Med."},{"key":"17182_CR34","volume":"2012","author":"M Stewart","year":"2012","unstructured":"Stewart, M. & Morling, J. R. Oral vasodilators for primary Raynaud\u2019s phenomenon. Cochrane Database Syst. Rev. 2012, CD006687 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"17182_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/20523211.2025.2514155","volume":"18","author":"B Tong","year":"2025","unstructured":"Tong, B. et al. A real-world study based on the FAERS database evaluating adverse drug reactions in three amphotericin B lipid formulations. J Pharm. Policy Pract. 18, 2514155 (2025).","journal-title":"J Pharm. Policy Pract."},{"key":"17182_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/s13023-025-03864-4","volume":"20","author":"L Xu","year":"2025","unstructured":"Xu, L. et al. Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database. Orphanet J. Rare Dis. 20, 315 (2025).","journal-title":"Orphanet J. Rare Dis."},{"key":"17182_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40264-023-01391-4","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. Enhancing transparency in defining studied drugs: The open-source living DiAna dictionary for standardizing drug names in the FAERS. Drug Saf. 47, 271\u2013284 (2024).","journal-title":"Drug Saf."},{"key":"17182_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo, P. M. et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul. 3, 1323057 (2024).","journal-title":"Front. Drug Saf. Regul."},{"key":"17182_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347","volume":"22","author":"Y Noguchi","year":"2021","unstructured":"Noguchi, Y., Tachi, T. & Teramachi, H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform. 22, bbab347 (2021).","journal-title":"Brief Bioinform."},{"key":"17182_CR40","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet, O., Carvajal, A., Escudero, A., Molokhia, M. & Cornelius, V. R. Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 36, 995\u20131006 (2013).","journal-title":"Drug Saf."},{"key":"17182_CR41","first-page":"123","volume":"113","author":"KK Temprano","year":"2016","unstructured":"Temprano, K. K. A review of Raynaud\u2019s disease. Mo. Med. 113, 123\u2013126 (2016).","journal-title":"Mo. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17182-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17182-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17182-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:03:34Z","timestamp":1760699014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17182-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17182"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17182-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The original version of this Article contained errors in Affiliation 1 and 2, where the university name was incorrectly given as \u201cFujian University of Chinese Medicine\u201d. The correct Affiliation 1 reads: \u201cFirst School of Clinical Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.\u201d, and Affiliation 2 reads: \u201cCollege of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, China.\u201d Furthermore, Affiliation 5 was incorrectly given as \u201cThe College of Health, Fujian Medical University, Fuzhou, 350122, China.\u201d The correct Affiliation 5 is \u201cSchool of Health, Fujian Medical University, Fuzhou, 350122, China.\u201d The original Article has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32059"}}